Aerovate Therapeutics Stock Downgraded After Trial Setback
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
- Latest
- Trending
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
The firm maintained its Buy rating despite highlighting a second-half sales increase as crucial to meet yearly targets amid a ...
Deutsche Bank's 3% DCF growth rate signals GDP alignment; Analyst warns Oracle's rating, target price risks. AI-assisted, editor-reviewed. Learn more ...
Exploring AI's role in education: A college student reveals AI is banned for paper writing, with institutions using tools to ...
Dogecoin could potentially secure an ETF by the market cycle's end, BitMEX's Hayes and Pal agree. DOGE trades at $0.13. ...
Direxion Daily Technology Bull 3X Shares (NYSEARCA:TECL) surged to $98.01; major investments from Bank of Nova Scotia, EP Wealth Advisors, ...
Charles Schwab Corp. faces near-term challenges like 2% cash outflows in May; Goldman Sachs maintains Neutral rating with a $75.00 ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Murray acquires 7,000+ DallasNews shares; exacting prices and Q2 earnings update ahead amid cash burn and unprofitability concerns.
Senate subpoenas Novo's Langa over drug pricing; Jorgensen to testify in September as Novo blames U.S. health system for high ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.